This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

DURING AN INSPECTION OF YOUR FIRM I OBSERVED:

**OBSERVATION 1**
The sponsor failed to submit an IND to the FDA prior to conducting a clinical investigation with an investigational new drug.

Specifically, study (b) (4) __________ and (b) (4) __________ were conducted without submitting INDs.

**OBSERVATION 2**
Legally effective informed consent was not obtained from a subject or the subject's legally authorized representative, and the situation did not meet the criteria in 21 CFR 50.23 - 50.24 for exception.

Specifically, subjects were enrolled and treated on the following studies without obtaining informed consent, with neither study appearing to meet the criteria for exception from informed consent:

A. (b) (4) __________ - 747 subjects; and,
B. (b) (4) __________ - at least 874 subjects.

**OBSERVATION 3**
Not all changes in research activity were approved by an Institutional Review Board prior to implementation.

Specifically,
A. For study (b) (4)

1. Serious adverse events (SAEs) were not reported to the IRB as required by the IRB, e.g.:

   Subject# | SAE                                                                 
   -------- |----------------------------------------------------------------------
   6       | airway complication, required intubation                             
   26      | hypoxia, required nasal cannula oxygen                              
   37      | hypoxia, required nasal cannula oxygen, nasal/oral airway, and jaw thrust 
   300     | hypoxia, required nasal cannula oxygen, face mask oxygen, and nasal/oral airway 
   346     | hypoxia, required nasal cannula oxygen                              
   498     | airway complication, required intubation                            
   594     | pupils became pinpoint                                              
   619     | hypoxia, required intubation                                        
   621     | dystonia.                                                           

2. An additional treatment regimen was added to the study, using treatment Haloperidol at 10 mg from 9/21/2017 to 10/12/2017, without IRB review or approval.
3. Seven-hundred and forty-seven (747) subjects in total were enrolled and treated on study a) over the 500 approved by the IRB, and b) over the 737 reported as the total enrollment to the IRB.

4. An IRB-required annual progress report was not submitted until about 6/29/2018, past the 5/22/2018 expiration of approval.

B. For study (b) (4)

1. Serious adverse events (SAEs) were not reported to the IRB as required by the IRB. e.g.:

<table>
<thead>
<tr>
<th>Subject#</th>
<th>SAE</th>
</tr>
</thead>
<tbody>
<tr>
<td>35</td>
<td>akathisia</td>
</tr>
<tr>
<td>56</td>
<td>hypoxia, required nasal cannula oxygen</td>
</tr>
<tr>
<td>74</td>
<td>airway complication, required intubation</td>
</tr>
<tr>
<td>105</td>
<td>hypoxia</td>
</tr>
<tr>
<td>134</td>
<td>hypoxia</td>
</tr>
<tr>
<td>157</td>
<td>hypoxia</td>
</tr>
<tr>
<td>192</td>
<td>hypotension</td>
</tr>
<tr>
<td>197</td>
<td>hypoxia, required intubation.</td>
</tr>
</tbody>
</table>

2. A study change was submitted to the IRB and approved to voluntarily suspend study activities effective 7/16/2018, with a subsequent change submitted 11/5/2018 stating the study was closed. However, it appears the study continued with the same treatment regimen and data collection activities.
until at least the most recent enrollment of Subject 874 on 11/19/2018; and, the status of the study is posted on clinicaltrials.gov as “Recruiting”. Changes in the study that do not appear to have been approved by the IRB include:

a) Continuing the study after the 7/16/2018 voluntary suspension submitted and approved;

b) Discontinuing provision of a Notification of Enrollment to subjects on about 7/16/2018; and,

c) Enrolling at least 874 subjects in total, over the 800 originally approved by the IRB.

3. An additional AMSS Data Validation sub-study was conducted without IRB review or approval.

**OBSERVATION 4**

An investigation was not conducted in accordance with the investigational plan.

Specifically, not all study conduct was in accordance with the study plans submitted to and approved by the IRB for (b) (4) ______and (b) (4) ______ c.g.:

A. There is no documentation to show all subjects were provided a Notification of Enrollment form, e.g.:

1. (b) (4) ______ subject 1, 7, 9, 14, 15, 23, 46, 48, 161, 179, 197, 205, 299, 326, 332, 464, 511, 587, 593, 594, 607, 613, 631, and 633; and,

2. (b) (4) ______ subject 8, 9, 10, 66, 72, 136, 171, 172, 197, 205, 206, 208, 209, 213, 214, 215, 216, 217, and 874.

B. There is no documentation to show all Research Volunteers (RVs) that conducted study operations were trained, e.g.:

1. (b) (4) ______

<table>
<thead>
<tr>
<th>RV</th>
<th>conducted study operations with</th>
</tr>
</thead>
<tbody>
<tr>
<td>ND</td>
<td>5, 8, 14, 173, 339, 343, 344</td>
</tr>
</tbody>
</table>
OBSERVATION 5

Failure to prepare or maintain adequate and accurate case histories with respect to observations and data pertinent to the investigation and informed consent.

Specifically, for study (b) (4) and (b) (4) there is no identification in source records to show who conducted:
A. screening, and completion of Screening Sheets for either study;
B. data collection from EMR, and completion of Chart Review form for either study; and,
C. data validation, and completion of the AMSS Data Validation form for study (b) (4).

OBSERVATION 6
Failure to ensure proper monitoring of the study.

Specifically, there is no documentation to show any monitoring of study (b) (4) for (b) (4).

**OBSERVATION 7**

Investigational drug disposition records are not adequate with respect to dates, quantity and use by subjects.

Specifically, no clinical investigator-required investigational drug disposition records were maintained for either study (b) (4) or (b) (4).

**OBSERVATION 8**

Lack of records covering receipt and disposition of an investigational drug.
Specifically, no sponsor-required investigational drug records were maintained for either study (b)(4).